Trial Profile
A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Oxaliplatin
- Indications Rectal cancer
- Focus Therapeutic Use
- 15 Jan 2014 Planned End Date changed to 1 Dec 2014 as reported by ClinicalTrials.gov record
- 02 Dec 2008 New trial record.